Year None202120202019201820172016 Date Latest Press Release October 16, 2018 Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH) October 16, 2018 Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint September 25, 2018 Eiger BioPharmaceuticals to Participate in Investor Conferences September 24, 2018 Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018 September 4, 2018 Eiger Announces Positive Meeting with FDA on Progeria Program August 27, 2018 Eiger BioPharmaceuticals to Participate in Investor Conferences August 13, 2018 Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia August 10, 2018 Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results August 7, 2018 Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference August 6, 2018 Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last »
